EUVIMEDEUVIMED entdecken
Crossref

How to Best Measure Disease Progression in Adult Spinal Muscular Atrophy Patients: A Clinical and Neurophysiological Study

Felipe Franco da Graça iD, Cristina Iwabe, Anamarli Nucci, Thiago Junqueira Ribeiro de Rezende, Marcondes Cavalcante França iD

Muscle & Nerve · 2026-04 · 73 (4) · 645-649

DOI: 10.1002/mus.70169 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Muscle & Nerve, online erschienen am 02.02.2026. Verfasst von Felipe Franco da Graça und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, School of Medical Sciences, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil. Hauptthemen laut MEDLINE: Disease Progression, Muscular Atrophy, Spinal. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 17 Literaturangaben. Gefördert von: Fundação de Amparo à Pesquisa do Estado de São Paulo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction/Aims Natural history data for adult patients with spinal muscular atrophy (SMA) remain scarce, which is particularly relevant in the current therapeutic era. This study aimed to identify the most sensitive clinical, patient‐reported, and neurophysiological measures to detect short‐term disease progression in untreated adult SMA patients.

Methods

This prospective, one‐year longitudinal study included 21 genetically confirmed adult patients with SMA types 2B and 3. Clinician‐reported outcomes (CROs) included the Motor Function Measure (MFM), Hammersmith Functional Motor Scale Expanded (HFMSE), and Revised Upper Limb Module (RULM). Additionally, patient‐reported outcomes (PROs) were assessed using the Modified Fatigue Impact Scale (MFIS). Neurophysiological evaluations included compound muscle action potential (CMAP) amplitude and motor unit number index (MUNIX) recorded from the ulnar nerve. Sensitivity to change was determined using standardized response means (SRMs), and associations between clinical and neurophysiological data were analyzed via Spearman correlation.

Results

The majority of participants were non‐ambulatory (16/21). The MFM total score was the only outcome to show a statistically significant decline over 12 months ( p = 0.02), with the highest SRM (−0.55), indicating superior sensitivity. MFM also demonstrated the strongest correlations with CMAP amplitude ( ρ = 0.90) and MUNIX ( ρ = 0.75), compared to other CROs. No significant longitudinal changes were observed in RULM, HFMSE, MFIS, CMAP, or MUNIX.

Discussion

Among evaluated outcome measures, the MFM was the most sensitive to short‐term progression and most closely aligned with neurophysiological markers. These findings support the use of MFM as a primary outcome in clinical trials involving adult SMA patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Disease ProgressionMuscular Atrophy, SpinalHumansFemaleMaleAdultLongitudinal StudiesProspective StudiesMiddle AgedYoung AdultAction PotentialsElectromyographyNerve Conduction StudiesUlnar NerveAdolescentPatient Reported Outcome Measures

Autor:innen und Institutionen

  • Department of Neurology, School of Medical Sciences, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.

ORCID-Profile: Felipe Franco da Graça, Marcondes Cavalcante França

Förderung

  • Fundação de Amparo à Pesquisa do Estado de São Paulo

Zitieren

APA

da Graça, F. F., Iwabe, C., Nucci, A., de Rezende, T. J. R., & França, M. C. (2026). How to Best Measure Disease Progression in Adult Spinal Muscular Atrophy Patients: A Clinical and Neurophysiological Study. Muscle & Nerve, 73(4), 645-649. https://doi.org/10.1002/mus.70169

Vancouver

da Graça FF, Iwabe C, Nucci A, de Rezende TJR, França MC. How to Best Measure Disease Progression in Adult Spinal Muscular Atrophy Patients: A Clinical and Neurophysiological Study. Muscle & Nerve. 2026;73(4):645-649. doi:10.1002/mus.70169

BibTeX
@article{daGraa2026,
  author = {da Graça, Felipe Franco and Iwabe, Cristina and Nucci, Anamarli and de Rezende, Thiago Junqueira Ribeiro and França, Marcondes Cavalcante},
  title = {How to Best Measure Disease Progression in Adult Spinal Muscular Atrophy Patients: A Clinical and Neurophysiological Study},
  journal = {Muscle & Nerve},
  year = {2026},
  volume = {73},
  number = {4},
  pages = {645--649},
  doi = {10.1002/mus.70169}
}
Kostenlos starten →